Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late ...

Swiss healthcare company Roche (RHHBY) on Friday said that the European Medicines Agency’s Committee for Medicinal Products ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Tandem Diabetes Care has agreed to pay Roche Holding $36 million to settle a patent infringement claim. The two companies have granted each other licenses to patents on the insulin delivery systems in ...

A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

Roche raised the curtain on its novel approach to DNA sequencing earlier this year, and now it's working with the Broad ...

"Integrating the SBX technology into clinical and translational pipelines opens exciting new possibilities,” said Niall ...